Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients

Cancer Journal

Volumn 14, Issue 3, 2008, Pages 200-206

  Chen, Miao Fen ^a,b   Tseng, Chih Jen ^a,b   Tseng, Ching Cheng ^a   Yu, Chun Yen ^a   Wu, Chun Te ^a   Chen, Wen Cheng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Adjuvant CCRT; Cervical cancer; IMRT; Toxicity; Tumor control

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RISK FACTOR; TREATMENT FAILURE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; DISEASE COURSE; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PELVIS; PROSPECTIVE STUDY; RADIATION EXPOSURE; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PELVIS; PROSPECTIVE STUDIES; RADIATION TOLERANCE; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 52649089690     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318173a04b     Document Type: Article

References (29)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-841.
2. Pieterse QD, Trimbos JB, Dijkman A, et al. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study. Int J Gynecol Cancer. 2006;16:1112-1118.
3. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymph-adenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177-183.
4. Bandy LC, Clarke-Pearson DL, Soper JT, et al. Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. Gynecol Oncol. 1987;26:160-168.
5. Barter JF, Soong SJ, Shingleton HM, et al. Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol. 1989;32:292-296.
6. Peters WA III, Liu PY, Barrett RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
7. Ryu HS, Chun M, Chang KH, et al. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol. 2005;96:490-495.
8. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781- 786.
9. Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol. 2005;74:251-258.
10. Vora SA, Wong WW, Schild SE, et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1053-1058.
11. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002;52:1330-1337.
12. Beriwal S, Jain SK, Heron DE, et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol. 2006;102:195-199.
13. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438-1444.
14. Lai CH, Hong JH, Hsueh S, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer. 1999;85:1537-1546.
15. Tsai CS, Lai CH, Wang CC, et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol. 1999;75:328-333.
16. Hong JH, Tsai CS, Lai CH, et al. Postoperative low-pelvic irradiation for stage I-IIA cervical cancer patients with risk factors other than pelvic lymph node metastasis. Int J Radiat Oncol Biol Phys. 2002;53:1284- 1290.
17. Small W Jr, Mell LK, Anderson P, et al. Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer. Int J Radiat Oncol Biol Phys. 2007 Nov 23; [Epub ahead of print].
18. Gerszten K, Colonello K, Heron DE, et al. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecol Oncol. 2006;102:182-188.
19. Salama JK, Mundt AJ, Roeske J, et al. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2006;65:1170- 1176.
20. Mundt AJ, Roeske JC, Lujan AE, et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001;82:456-463.
21. Ahamad A, D'Souza W, Salehpour M, et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys. 2005;62:1117-1124.
22. Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201-207.
23. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in Gynecology patients treated with intensity-modulated whole pelvis radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56:1354-1360.
24. Kodama J, Seki N, Nakamura K, et al. Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy. Gynecol Oncol. 2007;105:757- 761.
25. Choi CH, Lee JW, Kim TJ, et al. Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results. Int J Radiat Oncol Biol Phys. 2007;68:817-822.
26. Montz FJ, Holschneider CH, Solh S, et al. Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings. Gynecol Oncol. 1994;53:114-120.
27. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51:261-266.
28. Lujan AE, Mundt AJ, Yamada SD, et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:516-521.
29. Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356-1365.